Retinoblastoma is a rare childhood cancer that develops in the retina, affecting approximately 1 in 15,000 live births annually. It typically manifests as leukocoria (white pupil) or strabismus (crossed eyes) in affected children, usually under the age of five. The condition can be hereditary, linked to mutations in the RB1 gene, or sporadic.
Diagnosis involves a thorough eye examination and imaging tests like ultrasound or MRI to assess the extent of tumor involvement. Treatment options vary based on the tumor size and location and may include chemotherapy, radiation therapy, laser therapy, or surgery such as enucleation (removal of the affected eye). Early detection is critical for better outcomes, as late-stage retinoblastoma can metastasize beyond the eye, reducing treatment success rates. Long-term monitoring is essential due to the risk of recurrence and development of secondary cancers.
Objective: To evaluate the complications after primary and secondary enucleation in children with retinoblastoma Method: This prospective cohort study was conducted from January 1, 2017, to December…
Sessions are CPD-accredited by The CPD Group (UK) — one CPD credit for every hour of attendance.
Oral and poster slots for original Retinoblastoma work, reviewed by the scientific committee.
Meet ophthalmologists, vision scientists, and eye-care clinicians from around the world across three days.
Accepted abstracts are compiled into the conference proceedings and indexed in Scopus and Web of Science.
Plenary lectures from leading voices shaping Retinoblastoma research and practice.
Attend in person in Singapore or join virtually — same programme, same certificate.
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
The Retinoblastoma track is a dedicated stream within IOC 2027 covering the latest research, clinical innovation, and best practice in Retinoblastoma. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Ophthalmologists, optometrists, vision scientists, educators, doctoral students, and trainees with an interest in Retinoblastoma are all welcome — whether presenting or attending.
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Yes. IOC 2027 is a hybrid conference — attend the Retinoblastoma track in person in Singapore or join live online, with on-demand access afterward.
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
